Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04535544
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 17, 2020
Completion date February 5, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05461170 - SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. Phase 2
Completed NCT02732639 - A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) Phase 3
Completed NCT02731131 - A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) Phase 2
Completed NCT02765802 - A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Phase 2
Active, not recruiting NCT05229991 - Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Phase 3
Terminated NCT01861444 - An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) N/A
Active, not recruiting NCT03105310 - Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Phase 2
Recruiting NCT04166266 - Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection
Completed NCT01088659 - A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. Phase 3
Completed NCT00686790 - Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) Phase 3
Completed NCT02876419 - A Long Term Follow-up Study of Patients From the REP 301 Protocol